drugset / Trial / NCT03341299

A Comparative Study of LY900014 With Insulin Lispro (Humalog) in Participants With Type 1 Diabetes Mellitus

NCT03341299

Phase 1 Completed 36 enrolled Eli Lilly and Company
RandomizedCrossoverDouble-blindBasic science

Summary

The purpose of this study is to evaluate a new formulation of insulin lispro, LY900014, which is a drug that lowers blood sugar. The study will look at how the body processes LY900014, and the effect of LY900014 on blood sugar levels following a standard meal. For each participant, the study will consist of 4 periods and there will be approximately 12 weeks from screening to final study follow up.

Timeline

Start
2017-11-13
Primary completion
2018-04-03
Completion
2018-04-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Insulin Lispro Protein / enzyme biologic Subcutaneous